The FDA's approval of Zepbound marks a significant advancement, being the first prescription drug specifically targeting obstructive sleep apnea, particularly among patients with obesity.
Dr. Vivian Asare highlighted that the approval of Zepbound introduces a much-needed option for patients with obstructive sleep apnea, who often face limited treatment choices.
The decision by the FDA could increase pressure on insurance companies to broaden coverage for obesity medications, which is of great concern given current restrictive policies.
Eli Lilly's studies showed that patients receiving Zepbound experienced greater reductions in sleep apnea symptoms compared to those on a placebo, demonstrating its efficacy.
Collection
[
|
...
]